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Background: Alveolar soft part sarcoma(ASPS) is an orphan malignancy associated with a 
rearrangement of transcription factor E3(TFE3), leading to abnormal MET gene expression. 
We prospectively assessed the efficacy and safety of the tyrosine kinase inhibitor(TKI) 
crizotinib in patients with advanced or metastatic ASPS.  
 
Patients and methods: Eligible patients with reference pathology-confirmed ASPS received 
oral crizotinib 250 mg twice daily. By assessing the presence or absence of a TFE3 
rearrangement, patients were attributed to MET+ and MET- sub-cohorts. The primary 
endpoint was the objective response rate(ORR) according to local investigator. Secondary 
endpoints included duration of response(DOR), disease control rate(DCR), progression-free 
survival(PFS), progression-free rate(PFR), overall survival(OS) and safety. 
 
Results: Among 53 consenting patients, all had a centrally confirmed ASPS and 48 were 
treated. A total of 45 were eligible, treated and evaluable. Among 40 MET+ patients, 1 
achieved a confirmed PR that lasted 215 days and 35 had stable disease(SD) as best 
response(ORR:2.5%, 95%CI:0.6-80.6%). Further efficacy endpoints in MET+ cases were 
DCR:90.0%(95%CI:76.3-97.2%), 1-year PFS rate: 37.5%(95%CI:22.9-52.1%) and 1-year OS 
rate:97.4%(95%CI:82.8-99.6%). Among 4 MET- patients, 1 achieved a PR that lasted 801 
days and 3 had SD(ORR:25.0%,95%CI:0.6-80.6%) for a DCR of 100% (95%CI:39.8-
100.0%). The 1 year PFS rate in MET- cases was 50%(95%CI:5.8-84.5%) and the 1-year OS 
rate was 75%(95%CI:12.8-96.1%). One patient with unknown MET status due to technical 
failure achieved SD but stopped treatment due to progression after 17 cycles. The most 
common crizotinib-related adverse events were nausea(34/48[70.8%]), vomiting 
(22/48[45.8%]), blurred vision(22/48[45.8%]), diarrhoea(20/48[41.7%]) and 
fatigue(19/48[39.6%]). 
 
Conclusion: According to EORTC efficacy criteria for soft tissue sarcoma, our study 
demonstrated that crizotinib has activity in TFE3 rearranged ASPS MET+ patients. 
 
Clinical trial number: EORTC 90101, NCT01524926 
 
Keywords: Alveolar soft part sarcoma, ASPS, transcription factor E3 (TFE3) gene 
rearrangement, MET expression, MET tyrosine kinase inhibitor, crizotinib 
 
Prior presentations: None 
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Key message: ASPS is a rare sarcoma with early metastatic spread. Objective responses to 
the crizotinib are uncommon, but a considerable proportion of patients achieve objective 
shrinkage of RECIST 1.1 target lesions and long term disease control. According to STS 
efficacy criteria established by EORTC, crizotinib is an active compound for ASPS, given the 
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Alveolar soft part sarcoma(ASPS) is a rare soft tissue sarcoma(STS) with high metastatic 
potential, accounting for 0.5-1% of all STS.
1-7
Typical metastatic sites include 
brain,lungs,lymph nodes and bone.
2,4,5
According to the literature,the 5-year survival is only 




Complete excision of the primary tumour can cure ASPS, but due to late diagnosis and early 
metastatic spread it is not an option for all patients.
2
Patients with advanced, inoperable and/or 
metastatic disease qualify for systemic treatment,but conventional chemotherapy has little 
efficacy.
2,4
A number of targeted agents are currently being tested in ASPS.
 
 
ASPS is characterised by the presence of a somatic translocation between chromosomes 17 
and X(Supplementary Figure S1, S2),resulting in the ASPSCR1-TFE3 fusion 
gene(Supplementary Introduction and Figure S3).
5,8,9
The ASPSCR1-TFE3 fusion gene plays a 
critical role in the development of ASPS as it encodes a chimeric transcription factor,inducing 





In normal cells the hepatocyte growth factor(HGF) activates the MET receptor resulting in a 
downstream cascade of events that regulate cell proliferation and differentiation.
10
In a variety 
of cancers, MET gets abnormally activated leading to abnormal cell division and 




The presence of MET activation and overexpression in ASPS provides a rationale to 
therapeutically target MET in this disease.Crizotinib(Xalkori
®
,Pfizer Inc.) is a small molecule 
targeting:MET,anaplastic lymphoma kinase(ALK),and ROS proto-oncogene 1 receptor 
tyrosine kinase(ROS1).
12-15
Crizotinib interferes with the MET pathway by competitively 
inhibiting adenosine triphosphate(ATP) from binding to the receptor, therefore abrogates its 
phosphorylation.
12-15
This blocks the downstream cascade of events, thereby inhibiting the 
growth and survival of MET dependent cells.
12-15
Crizotinib is indicated in adult patients for 
ALK-positive non-small cell lung cancer(NSCLC),and ROS1-positive advanced 
NSLCL,
15
and the recommended oral dose in adults is 250 mg twice daily. 
 
The European Organization for Research and Treatment of Cancer(EORTC) initiated a 
multinational, multi-tumour, prospective phase 2 clinical trial(EORTC 90101 “CREATE”) to 
evaluate the efficacy and safety of crizotinib in patients with advanced tumours driven by 
MET and/or ALK alterations.CREATE included 6 disease-specific groups, and we report here 
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This was a multicentre,biomarker-driven,single agent,non-randomized,open-label,two-stage 
phase 2 trial,assessing crizotinib in patients with locally advanced/metastatic ASPS. The 
patient population was divided by protocol into MET altered(MET+) and MET non-
altered(MET-) sub-cohorts, assessed by the presence of TFE3 rearrangement. Both cohorts 
were analysed separately. 
 
Ethics approval was obtained for this study(ClinicalTrials.gov identifier NCT01524926), 
which was conducted in accordance with the Declaration of Helsinki,International Conference 





Patient enrolment was based on a multi-step registration procedure. Step 1 prerequisites for 
registration were a local diagnosis of advanced and/or metastatic ASPS deemed incurable by 
conventional surgery,radiotherapy or systemic therapy,the availability of a formalin-fixed 
paraffin embedded(FFPE) tumour-containing tissue block from primary tumour and/or 
metastatic site,and written informed consent of the patient for central collection of tissue and 
all other trial-specific procedures.  
 
Criteria for step 2 included receipt of the tissue by a central biorepository (BioRep, Milan, 
Italy) with presence of tumour in the shipped material and confirmation of the correct 
diagnosis of ASPS by central reference pathology. 
 
Screened patients were treated after completion of both steps,provided all other eligibility 
criteria were met. Details on patient selection and prior treatments are described in the study 
protocol (http://www.eortc.be/services/doc/protocols/90101v10.0.pdf). 
 
Documentation of the presence of TFE3 rearrangement was not required for a patient to enter 
the treatment phase(step 3). FISH analysis was done while patients were already receiving 
therapy,to avoid delaying start of treatment for patients in need for an experimental treatment. 
 
Treatment, safety and efficacy assessment 
 
Eligible patients with centrally confirmed ASPS were treated with oral crizotinib at a starting 
dose of 250mg twice daily. One treatment cycle was defined as 21 days. Treatment,dose and 
schedule modifications were defined in the protocol. 
 
Tumour assessments were done based on RECIST 1.1 using computer tomography or 
magnetic resonance imaging of chest,abdomen and pelvis. Baseline scans were not older than 
28 days at study entry. The radiological assessment was done locally every 6 weeks and 
repeated to confirm objective responses at least 4 weeks after the initial documentation of a 
response. Objective responses were reviewed centrally. 
 
Safety information was collected using the Common Terminology Criteria for Adverse 
Events(CTCAE) version:4.0. 
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Assessment of TFE3 rearrangement 
 
Patients were attributed to MET+ or MET- sub-cohorts on the basis of the presence or absence 
of a TFE3 gene rearrangement, assessed by fluorescence in situ hybridization(FISH) on 
interphase nuclei of paraffin-embedded 4 µm tumour tissue sections,using custom bacterial 
artificial chromosomes(BAC)RP11-344N17 and RP11-552J9 probes that flank the 
TFE3/Xp11.2 gene.The BAC clones were obtained from the BACPAC Resource 
Center(CHORI;Oakland,CA).DNA isolation,probe labeling and hybridization were performed 
as previously described.
16
Slides were scored by two independent investigators and considered 




The main objective was to study the activity of crizotinib in ASPS patients with TFE3 gene 
rearrangement(MET+).The primary endpoint was the ORR per RECIST 1.1 with response 
confirmation, assessed by the local investigator.This endpoint was chosen based on the 
response pattern seen with crizotinib in the labelled indication of NSCLC and due to the 
absence of reliable reference data on PFS or PFR in ASPS when the protocol was 
written.Secondary endpoints included:DOR,DCR,PFS,PFR,OS,overall survival rate(OSR), 
safety,and correlative/translational research endpoints.DCR was defined as the percentage of 




A Simon's optimal two-stage design was implemented separately for the ASPS MET+ and 
MET- sub-cohorts. The type I error and power were set at 10%. The study was conceptually 
focused on MET+ disease, while MET- patients served as a non-randomized, treated internal 
control. The entry of “all comers” independent of their MET status allowed centres to avoid 
delaying treatment for patients in need of an active intervention and to provide reference data 
for both subsets for future clinical trials. The entry of MET- cases was considered ethical due 
to the lack of validated treatment alternatives. 
 
In stage 1,if at least two out of the first 12 eligible and evaluable MET+ ASPS patients 
achieved a confirmed RECIST PR or CR, a maximum of 35 patients were to be enrolled. In 
stage 2,if <6 out of the 35 eligible and evaluable patients responded,the treatment was 
declared ineffective.If ≥6 out of the 35 patients(17%) responded,further study of crizotinib 
was warranted.Treatment activity was declared if response rate was >10%. 
 
Stopping rules and activity endpoints details are provided in Supplementary Methodology. 





Patient disposition, reference pathology, clinical screening and enrolment 
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Between 17 June 2013 and 29 June 2015,19 sites in 10 European countries recruited 53 
patients with the local diagnosis of ASPS. All patients had a centrally confirmed ASPS,which 
is likely a reflection of the routine use of FISH testing in this sarcoma subtype. 
 
Forty-eight patients were enrolled in the study and started treatment with crizotinib(safety 
population:43 MET+,4 MET-,1 MET?).Reasons for not entering the treatment phase in the 5 
remaining patients are shown in the trial profile(Supplementary Figure S5).Out of 48 patients 
who started treatment, 45 were eligible and evaluable for the primary and secondary 
endpoints(40 MET+,4 MET-,1 MET?).Two were found ineligible due to the use of specific 
concomitant medication or residual toxicity from prior therapy,one patient had surgery after 
one treatment cycle without further imaging.   
 
Recruitment to both the MET+ and MET- sub-cohorts was suspended on 26 June 2015,with 




FISH analysis was completed within a median time of 5 days after receipt of technically 
useful,unstained slides from the central biorepository.  
 
Among the 53 patients with centrally confirmed diagnosis, 48(90.6%) had TFE3 gene 
rearrangement and were defined as MET+,and 4(7.5%) had no rearrangement detected by 
FISH. In one remaining patient,FISH analysis could not be performed due to insufficient 
quality of the available biological material. This patient was defined as MET?.Supplementary 




Characteristics of the 48 treated patients are shown in table 1A.Their median age was 30 
years,75.0%(36/48) had an ECOG PS of 1,the majority(64.6%[31/48]) had undergone prior 
surgery,and 47.9%(23/48) had received systemic therapy. 
 
Among the total group with confirmed diagnosis of ASPS,43/48 MET+ patients,4/4 MET- 
patients,and the one MET? patient received crizotinib(Supplementary Figure S5). 
 
Crizotinib study treatment 
 
As of 19 May 2017,with a median follow-up of 833 days(range:85-1279),2/45 treated patients 
were still receiving active treatment(Supplementary Figure S5 and table 1B).The median 
relative dose intensity was 98.2%,with 27/45 treated patients requiring dose reductions or 
dose modifications. The treatment duration with crizotinib ranged from 2.4-156.1 weeks(table 
1B).Reasons for treatment discontinuation are shown in table.1B.   
 
Activity of crizotinib 
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Objective responses were observed in 1/40 MET+ patients(2.5%ORR; 95% confidence 
interval[CI]:0-13.2%) and in 1/4 MET- patients(25.0%;95%CI:0.6-80.6%).Key efficacy data 
are summarized in table 1C.The DOR was 215 days in the responding MET+ patient and 801 
days in the MET- patient.The responding patients progressed after 52 and 14 treatment cycles, 
respectively,and both are alive at the data cut-off. SD was observed in 87.5%(35/40) MET+ 
patients, in 75.0%(3/4) MET- patients,and in the one MET? patient. The remainder of patients 
had progression. The DCR was 90%(36/40) in MET+ patients(95%CI:76.3-97.2%),and 100% 
in MET-(95%CI:39.8-100.0%) and the one MET? patient.  
 
The PFR at 1 year was 37.5%(95%CI:22.9-52.1%), 50.0%(95%CI:5.8-84.5%) and 0% in 
MET+, MET-, and MET? patients,respectively. The 3 and 6 months cumulative PFR in MET+ 
patients were 85%(CI:73.9-96.1%) and 55.0%(39.6-70.4%),and in MET- 75.0% (95%CI:32.6-
100%) and 50.0%(1.0-99.0),respectively. Two-years PFR are shown in figure 1A and table 
1C. 
 
The 1 year OSR were 97.4 %(95%CI:82.8-99.6%) in MET+ patients and 75.0%(95%CI:12.8-
96.1%) in MET- patients. The OS at 2 years was 81.3%(95%CI:64.7-90.6%) in MET+ 
patients and unchanged in MET- patients(75.0%[95%CI:12.8-96.1%])(figure 1B and table 
1C).The long follow-up of this trial allows us to provide important information on the clinical 
course of advanced/metastatic ASPS,and serves as a useful resource for future research in this 
rare cancer. 
 
Figure 1C illustrates the maximum target lesion shrinkage,figure 1D summarizes the clinical 
course of the treated patients. 
 
 
Safety and toxicity 
 
No new, unexpected safety signals were detected in ASPS patients. The most 
common(overall, grade ≥1) crizotinib-related adverse events were nausea(34/48[70.8%]), 
vomiting (22/48[45.8%]),blurred vision(22/48[45.8%]),diarrhoea(20/48[41.7%]),and fatigue 
(19/48[39.6%]). 
 
Treatment-related grade 3/4 events were fatigue(two patients),hypotension grade 4 combined 
with bradycardia grade 4,blurred vision,diarrhoea and febrile neutropenia(one patient 
each).Adverse events details are shown in Supplementary Table S2 and S3. The 
Supplementary Results summarises serious adverse events.  
  
No deaths occurred on treatment or within 4 weeks of treatment discontinuation.  
 
 
Discussion   
 
Information from prospective clinical trials on the efficacy of systemic treatments for ASPS is 
limited. EORTC 90101 CREATE is one of the first ASPS-specific prospective studies. The 
main objective of this phase 2 study was to assess the activity of crizotinib in ASPS,a very 
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rare and chemotherapy-resistant, translocation-related sarcoma.The primary endpoint of the 
trial was not met, as we did not observe at least two objective and radiologically confirmed 
RECIST 1.1 responses among the first 12 eligible and evaluable MET+ cases. 
 
Multiple factors led to over recruitment of patients. The rapid accrual of ASPS cases,with 
more than half of the patients previously untreated,reflected the high unmet medical need for 
this orphan and hard to treat malignancy. Investigators observed a relevant proportion of 
patients achieving early disease stabilization with crizotinib,and all these cases could 
theoretically still convert, upon further exposure, to an objective response. Furthermore,all 
responses had to be confirmed by a second scan,to be in line with RECIST 1.1.This led to a 
delay in reporting efficacy data for trial participants,as investigators had to wait until their 
patients either came off study or had reached a confirmed PR. By that time we had exceeded 
the originally planned maximum sample size to assess the futility of crizotinib in MET+ 
ASPS.In the light of the lack of validated treatment alternatives for this malignancy we 
accepted this over recruitment.  
 
The majority of our trial participants had a centrally confirmed TFE3 gene rearrangement,and 
none of the study ASPS patients were misclassified according to central pathology review. 
This is likely a reflection of the increasing local use of molecular testing in many institutions 
in translocation-related STS.  
 
Of note, 4 patients had no detectable rearrangement of the TFE3 gene by FISH (classified as 
MET-).It is possible that these were false negative cases due to cryptic gene rearrangements 
that are under microscopic visibility. This could explain also the challenging observation that 
some of these MET- patients seemed to benefit from the treatment with crizotinib. 
Confirmation of ASPSCR1/TFE3 fusion by RT-PCR or other molecular techniques in these 
cases would be required to prove this notion. 
 
Even though TFE3 rearrangement, potentially leading to altered MET expression,was present 
in the majority of our patients,crizotinib’s inhibition of MET translated in only sporadic,but 
durable objective responses. It is unclear why two of our patients(one MET+, one MET-) had 
exceptional responses,but we hope that further tissue-based analysis will provide an 
explanation. We cannot exclude that the presence of the ASPSCR1-TFE3 fusion led to 
different level of altered MET expression/abnormal activation. On the other hand these 
responses might be induced by effects other than MET inhibition, as crizotinib affects more 
than one target.  
 
Interestingly,90% of our patients with TFE3 gene rearrangement achieved disease control and 
the duration of therapy was long(median number of 12.5 treatment cycles in MET+ patients), 
suggesting that PFS or PFR would have been better primary endpoints. The response pattern 
of MET-driven malignancies to crizotinib is clearly different than the impressive volumetric 
responses seen in ALK or ROS1 driven NSCLC. 
 
Based on a retrospective statistical analysis of multiple EORTC sarcoma trials,Van Glabbeke 
et al. proposed reference values for potentially active agents in STS.
17
For first line therapy, 
she recommended a 6 month PFR of >30-56% and for second line therapy a 3 month PFR of 
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>40% as an indicator of promising activity,while a 6 month PFR of <20% would suggest 
inactivity of a novel compound.In our ASPS MET+ group,the 3 and 6 months cumulative 
PFR were 85%(CI:73.9-96.1%) and 55.0%(39.6-70.4%).In an exploratory analysis of our 
study,in pretreated versus non-pretreated MET+ patients, the first-line subset had a 3 and 6 
month PFR of 52.6% (30.2-75.1) and 42.1%(19.9-64.3%).The second-line subset had a 3 and 
6 month PFR of 57.1%(20.5-93.8%) and 14.3%(0.0-40.2%).This post hoc analysis suggests 
that crizotinib is active in this setting following Van Glabbeke’s criteria. 
 
The PFS seen with crizotinib in MET+ ASPS is better than results achieved in non-selected 
patients with advanced STS treated with single-agent doxorubicin in first line(4.6 
months,95%CI:2.9-5.6),
18
or with the oral angiogenesis inhibitor pazopanib in previously 
treated STS patients(4.6 months,95%CI:3.7-4.8).
19
However,the biological behaviour of ASPS 
is so different from the majority of sarcomas,that the value of comparing the results of this 
study with all-comer STS studies is relatively limited. In a retrospective database review 
evaluating the efficacy of pazopanib and/or trabectedin in advanced ASPS patients, the 
median PFS for pazopanib(N=29) was 13.6 months(range:1.6-32.2+) at 19-month median 
follow-up,the median PFS for trabectedin(N=23) was 3.7 months(range:0.7-109) at 27-
months.
20
In our trial, in ASPS with TFE3 gene rearrangement (with about half of the patients 
previously treated), crizotinib(N=40) was associated a median PFS of 8.0 months(95%CI:4.1-
12.8) and the median OS was not reached after a median 833 days(range:85-1279).  
  
The tissue blocks collected from 53 ASPS patients are now the basis for multiple ongoing 
exploratory studies,to improve our understanding of the biology and the identification of new 
prognostic/predictive biomarkers and treatment strategies for this rare cancer. 
 
Our study showed variable responses,which suggests the presence of other factors in 
combination with TFE3 rearrangement which might predict efficacy of crizotinib. As the 
level of MET expression and/or activation may vary in different ASPS tumours,even with 
ASPSCR1-TFE3 fusion present,it should be thoroughly evaluated using 
immunohistochemistry for both total and activated forms of the signalling pathway 
components. Furthermore,the level of MET gene expression could be assessed utilising in situ 
hybridisation or quantitative polymerase chain reaction. This translational part of the project 
is on-going, using leftover material. In addition,we are currently performing correlative 
studies using whole exome sequencing to evaluate the mutational profile and perform low-
coverage whole genome sequencing to study copy number changes,which will be 
supplemented by research using tissue microarrays constructed from the tissue blocks,to 
better understand the molecular background of ASPS and the sensitivity or resistance of 
individual cases to crizotinib.  
 
The range of adverse events observed in this study was consistent with safety data for 
crizotinib in NSCLC patients. No new types of adverse events were observed in ASPS. Dose 
intensity was high and the incidence of dose modifications due to toxicity was moderate. 
 
This study illustrates some of the methodological limitations using response rate in early 
clinical trials in oncology. Our study’s primary endpoint was chosen based on the volumetric 
responses seen with crizotinib in the labelled indication of ALK+ NSCLC and due to the 
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absence of reliable reference data on PFS or PFR in ASPS. In general,EORTC is 
recommending the use of time-related endpoints such as PFR during the early exploration of 
novel agents in STS,
17
which provided the phase 2 rationale for at least two successful 




We currently see more trial activity in ASPS than in the past. Most trials focus on 
angiogenesis inhibitors,which can induce a clinically relevant reduction in tumour burden in 
individual patients. NCT01337401(CASPS),evaluating the efficacy and safety of cediranib vs 
placebo(with crossover to cediranib),used a somewhat artificial primary endpoint measuring 
the percentage change in the sum of target marker lesion diameters from baseline to week 
24(or progression if sooner). The study met its primary endpoint. PR was observed with 
cediranib in 6/28 ASPS patients vs 0/16 patients on placebo,SD occurred in 19/28(68%) of 
patients on cediranib and 12/16(75%) on placebo. The median PFS was 10.8 months for 
cediranib vs 3.7 months for placebo(Hazard Ratio:0.54 [90%CI:0.30-0.97,p=0.041]).
22 
Cediranib is also being tested in two other studies(NCT00942877 and NCT01391962). Other 
antiangiogenic agents under evaluation in ASPS are pazopanib(NCT02113826) and sunitinib 
(NCT01391962). 
 
In this study in patients with advanced or metastatic ASPS with central determination of 
rearrangement of TFE3,we were able to demonstrate that crizotinib is an active compound for 
ASPS,given the DCR and PFR observed in this histotype-specific trial. We would recommend 
for future early clinical trials involving novel targeted therapies for ASPS that endpoints such 
as DCR, PFS and/or PFR should be considered.  
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Figure 1A. Kaplan-Meier estimates for progression-free survival for the MET+ and MET- 
sub-cohorts per protocol. 
 
Figure 1B. Kaplan-Meier estimates for overall survival for the MET+ and MET- sub-cohorts 
per protocol. 
 
Figure 1C. Maximum shrinkage of RECIST 1.1 target lesions (per protocol) in the MET+, 
MET-, and MET? sub-cohorts, according to local investigator’s assessment. 
 
Figure 1D. Clinical course of patients in the ASPS MET+, MET- and MET? sub-cohorts 
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Figure 1A. Kaplan-Meier estimates for progression-free survival for the MET+ and MET- sub-cohorts per 
 protocol. Legend: The vertical bars represent the 95% confidence intervals for the 1- and 2-year 
progression-free survival (PFS) rates. The median PFS in MET+ patients was 8.0 months (95% CI: 4.1-
12.8).  
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Figure 1B. Kaplan-Meier estimates for overall survival for the MET+ and MET- sub-cohorts per 
 protocol. Legend: The vertical bars represent the 95% confidence intervals for the 1- and 2-year overall 
survival (OS) rates. The median OS has not been reached.  
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Figure 1C. Maximum shrinkage of RECIST 1.1 target lesions (per protocol) in the MET+, MET-, and MET? 
sub-cohorts, according to local investigator’s assessment.  
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Figure 1D. Clinical course of patients in the ASPS MET+, MET- and MET? sub-cohorts.  
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Table 1. Patient characteristics, study treatment, and response assessment and efficacy 
summary. 
 
Table 1A. Key patient characteristics.  










 N (%) N (%) N (%) N (%) 
Age (years)                                                                                  
     Median                                                                                 30               41               35               30              
     Range                                                                                   16 - 54        22 - 69        n/a        16 - 69        
Eastern Cooperative Oncology Group performance 
status  
    
     0                                                                                           33 (76.7)                   2 (50.0)                   1 (100.0)                36 (75.0)                
     1                                                                                            9 (20.9)                     2 (50.0)                  0 (0.0)                   11 (22.9)                
     2                                                                                           1 (2.3)                        0 (0.0)                    0 (0.0)                   1 (2.1)                    
Sex                                                                                                
     Male                                                                                     22 (51.2)                   3 (75.0)                   1 (100.0)                26 (54.2)                
     Female                                                                                 22 (51.2)                   3 (75.0)                   1 (100.0)                26 (54.2)                
Any previous major surgery    28 (65.1)                   2 (50.0)                   1 (100.0)                31 (64.6)                
Any previous systemic anticancer therapy 21 (48.8)                   1 (25.0)                   1 (100.0)                23 (47.9)                
     Chemotherapy 10 (23.3)                   0 (0.0)                     1 (100.0)                11 (22.9)                
     Tyrosine kinase inhibitor 13 (30.2) 1 (25.0) n/a 14 (29.2) 
     Mammalian target of rapamycin inhibitor 2 (4.6) n/a  n/a 2 (4.2) 
     Autologous stem cell reinfusion for ASPS 1 (2.3) n/a n/a 1 (2.1) 
Legend: Patients were attributed to MET sub-cohorts on the basis of the presence or absence 
of a TFE3 gene rearrangement assessed by fluorescence in situ hybridization (FISH). MET+, 
MET altered (>15% of at least 100 cells showed split signals); MET-, MET non-altered; 
MET?, FISH analysis could not be performed due to insufficient quality of the available 
biological material; n/a, not applicable.  
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Table 1B. Treatment, dose intensity and dose adjustments. 










 N (%) N (%) N (%) N (%) 
Treatment, dose intensity and dose adjustments:     
     
Relative dose intensity (%)                                                                                                    
     Median                                                                                                                                                                     98.1 98.3               98.3 98.2               
     Range                                                                                                                                            57.8 - 101.1       95.8 - 100.3 98.3 - 98.3        57.8 - 101.1       
     
Number of patients with at least one treatment 
modification  
25 (58.1)                                                                                        1 (25.0)                     1 (100.0)                                                                          27 (56.3)                                                               
     Reduction to dose level -1 (200 mg twice daily) 9 (22.5)                                                                                        0 (0.0)                            0 (0.0)                                         9 (20.0)                                                          
     Reduction to dose level -2 (250 mg once daily)  3 (7.5)                                                               0 (0.0)                                                       0 (0.0)                                                                                      3 (6.7)
     Other dose level modification            0 (0.0)                                                                                         0 (0.0) 0 (0.0)                                                                            0 (0.0)                                                                                     
     Interruption of treatment          16 (40.0)                                                                                        1 (25.0)                           1 (100.0)        18 (40.0)                                                         
     
Treatment duration:     
     
Duration of treatment (weeks)                                                                                                   
     Median                                                                                                                       39.5 45.0 50.9 42.0 
     Range                                                                                                                        2.4 - 113.3 13.7 - 156.1 50.9 - 50.9 2.4 - 156.1 
     
Number of cycles                                                                                                               
     Median                                                                                                                       12.5 15.5 17.0 13.0 
     Range                                                                                                                        1.0 - 38.0 5.0 - 52.0 17.0 - 17.0 1.0 - 52.0 
     
     
Reasons for treatment discontinuation:     
     
Treatment status                           
     Ongoing                       2 (5.0)                                                                                      0 (0.0)                                0 (0.0)                                                                            2 (4.4)                      
     Stopped                       38 (95.0)                                                                                        4 (100.0)                            1 (100.0)                                                                          43 (95.6)                     
     
Major reason for protocol treatment discontinuation         
     Progression of ASPS                                                   32 (84.2)                                                                                        3 (75.0)                           1 (100.0)                                       36 (83.7)                                                         
     Toxicity                                              2 (5.3)                                                                                         0 (0.0)                             0 (0.0)                                          2 (4.7)                                                         
          Hepatic toxicity 1    
          Multiple adverse events (diarrhea, vomiting,    
          dizziness, headache, blurred vision, rash, nausea) 
1    
     Patient decision                                    3 (7.9)                                                                                         0 (0.0)                             0 (0.0)                                                                            3 (7.0)                       
     Symptomatic deterioration without radiological  
     evidence of PD/relapse              
0 (0.0) 1 (25.0) 0 (0.0)                                                                                         1 (2.3) 
     Other        1 (2.6) 0 (0.0) 0 (0.0)                                                                                         1 (2.3) 
          Discontinuation for resection of target lesions 1    
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Table 1C. Response assessment and efficacy summary, according to investigator assessment. 










 N (%) N (%) N (%) N (%) 
Best RECIST 1.1 response      
     Complete response                       - - - - 
     Partial response                 1 (2.5) 1 (25.0) 0 (0.0) 2 (4.4) 
     Stable disease                   35 (87.5) 3 (75.0) 1 (100.0) 39 (86.7) 
     Progressive disease              4 (10.0) 0 (0.0) 0 (0.0) 4 (8.9) 
Objective response rate               2.5% 25.0% 0% 4.4% 
     (95% CI ) (0-13.2%) (0.6-80.6%) (0-97.5%) (0-15%) 
Disease control rate 90.0% 100.0% 100.0% 91.1% 
     (95% CI) (76.3-97.2)% (39.8-100.0%) (2.5-100.0)% (78.8-97.5)% 
Progression-free survival                           
     Alive with no evidence of disease                                      6 (15.0) 1 (25.0) 0 (0.0) 7 (15.6)                                                                                        
     Progression of ASPS or died                                       34 (85.0) 3 (75.0) 1 (100.0) 38 (84.4)                                                                                        
     1-year progression-free survival rate  









     2-year progression-free survival rate  









      Median (months) 




(2.8-infinity) -  
8.1 
(4.2-12.8) 
Survival status         
     Alive              29 (72.5) 3 (75.0) 0 (0.0) 32 (71.1) 
     Dead           11 (27.5) 1 (25.0) 1 (100.0) 13 (28.9) 
         Reason of death  :                                  
            Progression of ASPS                         9 (22.5) 1 (25.0) 1 (100.0) 11 (24.4)  * 
            Unspecified (information received  
            via a registry) 
2 (5.0)    
     1-year survival rate  




(12.8-96.1%)  -  95.4% (82.7-98.8%) 
     2-year survival rate  




(12.8-96.1%)  -  81.2% (65.9-90.1%)        
      Median (months) 
      (95%CI) not reached - - not reached 
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